Last reviewed · How we verify
SNX-5422 Mesylate Hsp90 inhibitor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SNX-5422 Mesylate Hsp90 inhibitor (SNX-5422 Mesylate Hsp90 inhibitor) — Esanex Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SNX-5422 Mesylate Hsp90 inhibitor TARGET | SNX-5422 Mesylate Hsp90 inhibitor | Esanex Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SNX-5422 Mesylate Hsp90 inhibitor CI watch — RSS
- SNX-5422 Mesylate Hsp90 inhibitor CI watch — Atom
- SNX-5422 Mesylate Hsp90 inhibitor CI watch — JSON
- SNX-5422 Mesylate Hsp90 inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). SNX-5422 Mesylate Hsp90 inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/snx-5422-mesylate-hsp90-inhibitor. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab